### Edgar Filing: Zelenkofske Steven - Form 4

Zelenkofsk	e Steven									
Form 4	0010									
January 25, 2019 FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSION								OMB APPROVAL		
	this box		SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549					3235-0287		
if no lo	nger		F CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES					Expires:	January 31, 2005	
subject Section Form 4	to SIATEN 16. or							Estimated burden hou response	average Irs per	
Form 5 obligat may co <i>See</i> Ins 1(b).	ions Section 17	(a) of the l	Public U	Jtility Hol	ding Co		nge Act of 1934, of 1935 or Secti 940			
(Print or Type	e Responses)									
1. Name and Zelenkofsl	Address of Reporting ke Steven	Person <u>*</u>	2. Issuer Name <b>and</b> Ticker or Trading Symbol ACHILLION			5. Relationship of Reporting Person(s) to Issuer				
			PHARMACEUTICALS INC [ACHN]				(Check all applicable)			
(Last)	(Last) (First) (Middle)			of Earliest T Day/Year)	ransaction		X Officer (gi below)	XOfficer (give titleOther (specify below) below) Chief Medical Officer		
C/O ACH PHARMA GEORGE	CEUTICALS, IN	C., 300	01/23/2	2019						
(Street)			Filed(Month/Day/Year)			Applicable Line)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
NEW HAY	VEN, CT 06511							More than One R		
(City)	(State)	(Zip)	Tab	ole I - Non-I	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	3. Transactio Code (Instr. 8)	Disposed (Instr. 3,	(A) or of (D) 4 and 5) (A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect	
				Code V		(D) Price				
Reminder: Ro	eport on a separate line	e for each cl	ass of sec	urities benef	Perso inforr requi	ons who res nation cont red to resp	or indirectly. spond to the collectained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

number.

### Edgar Filing: Zelenkofske Steven - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy)	\$ 2.18	01/23/2019		А	200,000	<u>(1)</u>	01/23/2029	Common Stock	200,000

# **Reporting Owners**

Reporting Owner Name / Address	Relationships					
r g a transmission and	Director	10% Owner	Officer	Other		
Zelenkofske Steven C/O ACHILLION PHARMACEUTICALS, INC. 300 GEORGE STREET NEW HAVEN, CT 06511			Chief Medical Officer			
Signatures						
/s/Steven						

Zelenkofske 01/25/2019 <u>\*\*</u>Signature of Date Reporting Person

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter.

#### **Remarks:**

See Exhibit 24.1, Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.